结核分枝杆菌Rv1009结构域基因的克隆、表达及亲和层析纯化

目的:克隆结核分枝杆菌Rv1009结构域基因,经序列测定正确后进行融合表达和纯化。方法:采用PCR从结核分枝杆菌H37Rv基因组中扩增出Rv1009结构域基因,用限制性内切酶消化后插入pUC-19克隆载体中,经测序正确后亚克隆到融合表达载体pPro-EXHT中,转化大肠杆菌DH5α,目的基因经IPTG诱导,由T7启动子调控表达了N端带6个连续组氨酸残基的Rv1009结构域多肽,在变性条件下对目的蛋白进行纯化。结果:获得了结核分枝杆菌Rv1009结构域基因,得到融合6个组氨酸残基的Rv1009结构域多肽,纯化获得的蛋白纯度大于87%。结论:构建了结核分枝杆菌Rv1009结构域基因的重组表达载体,并获得了高纯度的融合表达蛋白,为后续深入研究奠定了基础。     

结核分枝杆菌Rv0859基因的克隆、表达、纯化及蛋白的亚细胞定位

本研究体外克隆了结核分枝杆菌Rv0859基因, 融合表达并纯化了Rv0859蛋白。首先提取H37Rv标准菌株中的基因组DNA, 设计Rv0859基因两端的引物, 以H37Rv基因组DNA为模板通过PCR方法扩增Rv0859基因。用Hind III和BamHⅠ两种限制性内切酶双切Rv0859基因, T4连接酶连接到pET30载体上, 再转入大肠杆菌JF1125中, 经过筛选鉴定后抽提质粒测序, 得到重组正确载体, 转化到表达宿主大肠杆菌BL21中。用IPTG进行诱导表达, 通过聚丙酰胺凝胶电泳(SDS-PAGE)及质谱鉴定重组表达蛋白。0.05 mol/L浓度的IPTG 37°C诱导4 h重组蛋白的表达量最高。制备重组蛋白的多克隆抗体, 通过亚细胞分离及Western-blotting分析蛋白的亚细胞定位。结果成功地构建原核表达载体pET30a-Rv0859, 并获得47845 D左右的大量表达的Rv0859蛋白, Western-blotting结果表明Rv0859蛋白主要定位于细胞膜中, 微量存在于细胞壁中, 为进一步的Rv0859蛋白功能研究奠定了一定的基础。     

结核分枝杆菌Rv3425蛋白的原核表达纯化及其血清学诊断价值

目的：用原核系统表达结核分枝杆菌Rv3425蛋白并纯化,评价该重组蛋白在结核病血清学诊断方面的价值。方法：以结核分枝杆菌H37Rv株基因组为模板,PCR扩增得到Rv3425基因序列,克隆至表达载体pET-28a中,转入大肠杆菌BL21（DE3）进行诱导、表达后纯化,用Western印迹和ELISA法进行抗原性初步评价。结果：在原核系统内经IPTG诱导表达后,Rv3425蛋白主要以包涵体形式存在,经复性和镍柱层析纯化后,纯度达95%以上;Western印迹和ELISA结果证明重组Rv3425具有较强的抗原活性;用纯化的Rv3425蛋白做抗原,临床诊断结核病人血清,阳性率达50%。结论：高纯度的Rv3425蛋白在结核病诊断方面具有很高的应用价值,可作为结核病诊断的备选抗原。     

结核分枝杆菌持续感染期抗原Rv1733c 的表达、纯化和鉴定

目的:克隆结核分枝杆菌持续感染期抗原Rv1733c基因,构建其原核表达载体,并在大肠杆菌中进行表达和纯化。方法:采用聚合酶链反应(PCR)方法从结核分枝杆菌H37Rv基因组中扩增出Rv1733c基因片段,克隆入pMD18-T载体,序列测定正确后将其亚克隆入原核表达载体pPro-EXHTb,并在大肠杆菌DH5α中进行表达,表达蛋白经SDS-PAGE及Western-blot分析后,以Ni-NTA亲和层析纯化蛋白。结果:成功克隆了Rv1733c基因片段并构建了其原核表达载体pPro-EXHTb-1733c,转化E.ColiDH5α后能表达大小约30 KD的蛋白,Western-blot分析表明表达产物正确。通过亲和层析获得纯化蛋白。结论:成功构建结核分枝杆菌持续感染期抗原Rv1733c原核表达载体pPro-EXHTb-1733c,并获得纯化蛋白,为研究新型结核疫苗的靶抗原奠定了基础。     

结核分枝杆菌Rv1168c蛋白的基因表达、纯化及结构分析

【目的】应用原核表达体系对结核分枝杆菌PPE蛋白家族Rv1168c进行高效表达,进一步进行蛋白纯化和结构分析。【方法】以结核分枝杆菌H37Rv基因组为模板,扩增Rv1168c基因,构建pET32a-Rv1168c重组质粒;转化重组质粒到大肠杆菌DH5α并在BL21(DE3)诱导表达,通过十二烷基硫酸钠-聚丙烯酰胺电泳(SDS-PAGE)鉴定Rv1168c在大肠杆菌中的表达情况;Ni-NTAHis﹡Bind Resin纯化重组蛋白Rv1168c;SDS-PAGE和质谱分析测定相对分子量后,用圆二色光谱(CD)和同源模建方法分析和检测重组蛋白Rv1168c的二级和三级结构。【结果】成功克隆了971bp的目的基因Rv1168c,并获得了高纯度的重组蛋白Rv1168c。重组蛋白的分子量为51.5kDa(含载体蛋白)。25℃时重组蛋白Rv1168c的二级结构包括34.4%α螺旋,33.7%β转角,31.9%无规则卷曲,它的三维模型显示为(β/α)5结构。【结论】成功得到高纯度的重组目的Rv1168c蛋白,并初步进行了结构分析,为进一步对Rv1168c结构和功能研究奠定了基础。     

结核分枝杆菌Rv1884c基因的克隆及其原核表达

目的:构建结核分枝杆菌Rv1884c基因的原核表达质粒,获得结核分枝杆菌Rv1884c基因的表达蛋白。方法:制备结核分枝杆菌基因组DNA,采用聚合酶链反应技术扩增目的基因片段;通过pGEX-4T-1构建质粒载体pGEX-4T-1-Rv1884c,经序列测定证实正确后转化大肠杆菌DH5α,再经IPTG诱导表达GST-1884融合蛋白;用聚丙烯酰胺凝胶电泳分析重组蛋白的相对分子质量及表达形式。结果:扩增出了结核分枝杆菌Rv1884c基因,构建了具有正确基因序列的质粒载体pGEX-4T-1-Rv1884c,转化大肠杆菌DH5α后经诱导产生了高水平的表达产物。结论:构建了pGEX-4T-1-Rv1884c质粒载体,并诱导表达了GST-1884融合蛋白,为进一步研究Rv1884c蛋白的活性及其功能,探讨结核分枝杆菌快速促生长作用奠定了基础。     

结核分枝杆菌Rv1759c结构域与IL-2融合蛋白的表达与鉴定

目的：构建结核分枝杆菌（MTB）Rv1759c结构域（Rv1759cD domain,Rv1759cD）与人IL-2（hIL-2）融合基因,并在大肠杆菌中表达获得重组的融合蛋白Rv1759cD-IL-2。方法：用PCR方法从MTB H37Rv基因组扩增Rv1759cD基因片段,测序后与hIL-2基因构建融合基因,并克隆到表达载体pProEX HTa。融合基因在大肠杆菌DH5α中诱导表达,经SDS-PAGE分析后,分别与His mAb、IL-2mAb和结核病人血清进行Western-blot鉴定,采用Ni-NTA亲和层析纯化蛋白。结果：获得的Rv1759cD基因经测序与GenBank公布的序列完全一致,与hIL-2基因连接后,构建的融合基因在大肠杆菌中有效表达。表达蛋白相对分子量为30KDAa,与预测值相符;Western-blot结果显示,在相对分子量30KDAa处分别与His mAb和鼠抗IL-2 mAb形成结合带,并与结核病人血清出现特异性结合。通过Ni-NTA亲和层析,可得到纯化的目的蛋白。结论：成功表达、纯化和鉴定了Rv1759cD-IL-2融合蛋白,并有可能作为新型结核病疫苗的靶抗原。     

结核分枝杆菌Rv1759c 结构域与IL-2 融合蛋白的表达与鉴定

目的:构建结核分枝杆菌(MTB)Rv1759c结构域(Rv1759cD domain,Rv1759cD)与人IL-2(hIL-2)融合基因,并在大肠杆菌中表达获得重组的融合蛋白Rv1759cD-IL-2。方法:用PCR方法从MTB H37Rv基因组扩增Rv1759cD基因片段,测序后与hIL-2基因构建融合基因,并克隆到表达载体pProEX HTa。融合基因在大肠杆菌DH5α中诱导表达,经SDS-PAGE分析后,分别与His mAb、IL-2mAb和结核病人血清进行Western-blot鉴定,采用Ni-NTA亲和层析纯化蛋白。结果:获得的Rv1759cD基因经测序与GenBank公布的序列完全一致,与hIL-2基因连接后,构建的融合基因在大肠杆菌中有效表达。表达蛋白相对分子量为30KDAa,与预测值相符;Western-blot结果显示,在相对分子量30KDAa处分别与His mAb和鼠抗IL-2 mAb形成结合带,并与结核病人血清出现特异性结合。通过Ni-NTA亲和层析,可得到纯化的目的蛋白。结论:成功表达、纯化和鉴定了Rv1759cD-IL-2融合蛋白,并有可能作为新型结核病疫苗的靶抗原。     

结核分枝杆菌Rv3369基因的表达和纯化

在大肠杆菌中高效表达结核分枝杆菌Rv3369蛋白,获得纯化的重组蛋白rRv3369。通过聚合酶链反应(Polymerase chain reaction,PCR)扩增Rv3369基因;以质粒pET28a为表达载体,构建重组质粒,转化大肠杆菌BL21(DE3);以异丙基硫代半乳糖苷(IPTG)诱导表达目的蛋白,通过SDS-PAGE鉴定rRv3369在大肠杆菌中的表达,确定rRv3369在大肠杆菌中的表达形式;采用Ni-NTA His.Bind Resin来纯化重组蛋白。重组质粒pET28a-Rv3369中目的基因测序结果与报道序列相同。分子量约19.5kDa,表达量约占菌体总蛋白的18%,纯化后的重组蛋白样品经SDS-PAGE和激光密度扫描分析表明其纯度为90%以上,每100mL培养菌可获得1.56mg左右的重组蛋白。用亲和层析法纯化的重组蛋白纯度较好。     

结核分枝杆菌HspX蛋白的原核高效可溶性表达及产物抗原性分析

目的:利用原核系统可溶性表达结核分枝杆菌HspX蛋白并进行纯化,通过免疫印迹反应初步鉴定重组蛋白的抗原性和特异性。方法:采用PCR方法,从结核分枝杆菌H37Rv基因组中扩增HspX核酸序列,克隆至原核表达载体pET-28a中,转入大肠杆菌BL21(DE3)进行诱导、表达和纯化,用Western印迹初步评价HspX的抗原性。结果:经IPTG诱导,HspX蛋白在原核系统内获得了可溶性表达,经镍柱亲和层析获得了纯度达95%以上的重组蛋白。Western印迹结果证明重组HspX蛋白与结核病患者血清标本呈强阳性反应,与健康人血清标本呈阴性反应。结论:重组蛋白HspX在大肠杆菌中以可溶性形式表达,高纯度的重组融合蛋白有可能成为结核病的血清学诊断抗原。     

Comparative proteome analysis of culture supernatant proteins of Mycobacterium tuberculosis H37Rv and H37Ra

To examine the virulence factors of Mycobacterium tuberculosis H37Rv, the proteome was used to characterize the differences in protein expression between virulent M. tuberculosis H37Rv and attenuated M. tuberculosis H37Ra. Two-dimensional gel electrophoresis was performed to separate culture supernatant proteins extracted from M. tuberculosis H37Rv and M. tuberculosis H37Ra. The protein spots of interest were identified by mass spectrometry, and then the genes encoding the identified proteins were cloned and sequenced. Comparison of silver-stained gels showed that three well-resolved protein spots were present in M. tuberculosis H37Rv but absent from M. tuberculosis H37Ra. Protein spot no. 1 was identified as Rv2346c. Protein spot no. 2 was identified as Rv2347c, Rv1197, Rv1038c, and Rv3620c, which shared significant homology and had the same peptide fingerprinting using tryptic digestion. No M. tuberculosis protein matched protein spot no. 3. Rv2346c, Rv2347c, Rv1038c, and Rv3620c of M. tuberculosis H37Rv were located on the M. tuberculosis H37Ra chromosome, and multiple mutations were observed in the corresponding areas of M. tuberculosis H37Ra. Codon 59 (CAG, Gln) of Rv2347c and Rv3620c was replaced by termination codon (TAG) in M. tuberculosis H37Ra, which probably terminated the polypeptide elongation. These results demonstrate the importance of studying the gene products of M. tuberculosis and show that subtle differences in isogenic mutant strains might play an important role in identifying the attenuating mutations.     

Identification of unique genetic markers in Rv0927c among Mycobacterium tuberculosis W-Beijing strains

Fifty-six clinical isolates of Mycobacterium tuberculosis were analyzed by spoligotyping to determine the prevalence of W-Beijing strains. Forty-nine of the 56 isolates belonged to W-Beijing strains and 7 isolates were non-Beijing strains. Comparative two-dimensional gel electrophoresis analysis of protein patterns between the W-Beijing and non-Beijing strains identified a unique protein Rv0927c that is absent in the former but present in the latter and the reference strain M. tuberculosis H37Rv. Compared with 7 non-Beijing clinical isolates and H37Rv, all 49 W-Beijing strains had two characteristic mutations, a deletion of AGC at nucleotide position 421 of Rv0927c gene encoding a putative short dehydrogenase/reductase, causing deletion of serine codon at amino acid position 141 and a -127 G-->A mutation in Rv0927c-pstS3 intergenic region, resulting in failure to express Rv0927c. Western blot analysis indicated that polyclonal antibody raised against H37Rv Rv0927c overexpressed in Escherichia coli reacted with non-Beijing strains and H37Rv but not W-Beijing strains. Characteristic mutations of Rv0927c that are present in W-Beijing strains can be used as a novel genetic marker for rapid molecular typing of M. tuberculosis W-Beijing strains.     

δ-睡眠肽与GFP融合蛋白的表达和纯化

构建δ-睡眠肽(DSIP)蛋白与GFP的融合基因表达载体,高效表达和纯化GFP-DSIP融合蛋白。通过SOE-PCR拼接DSIP全长编码基因,并使得DSIP上游具有肠激酶识别位点,经双酶切定向克隆至表达载体pET-28a,构建重组载体pET-28a-DSIP,通过PCR扩增GFP全长编码基因,经双酶切定向克隆至pET-28a-DSIP,构建原核重组表达载体pET-28a-GFP-DSIP,通过双酶切和测序鉴定后,导入E.coli BL21宿主菌中,IPTG诱导表达融合蛋白,采用镍亲和层析和分子筛凝胶层析获得高纯度蛋白,SDS-PAGE分析鉴定。经测序鉴定成功构建了原核重组表达载体pET-28a-GFP-DSIP,在IPTG诱导下获得可溶性的绿色荧光蛋白与睡眠肽的融合蛋白,经Ni-NTA亲和层析纯化成功获得高纯度的融合蛋白。成功构建了DSIP与GFP融合基因的重组表达载体,确定了GFP-DSIP融合蛋白诱导表达的最佳条件,获得了较高纯度的融合蛋白,为进一步研究DSIP蛋白的生物学功能奠定了基础。     

结核分枝杆菌Rv1884基因真核表达质粒的构建及表达

目的:构建结核分枝杆菌Rv1884基因真核表达载体。方法:PCR扩增Rv1884基因,测序正确后克隆入真核表达载体pcDNA3.1(-);经酶切鉴定正确的重组质粒酶以阳离子聚合物转染P815细胞后,以RT-PCR方法检测mRNA的表达,以间接免疫荧光技术检测目的蛋白的表达。结果:构建了重组质粒pcDNA-Rv1884;RT-PCR结果证明Rv1884可在P815细胞中转录;用间接免疫荧光检测,表达有Rv1884蛋白的细胞着染。结论:构建了结核分枝杆菌Rv1884基因的真核表达载体pcDNA-Rv1884,Rv1884基因可以在P815细胞中表达。     

The diagnostic performance of recombinant Trypanosoma cruzi ribosomal P2beta protein is influenced by its expression system

In the present work, we have determined the effect of expression vectors and their corresponding host bacteria on the antigenic performance of Trypanosoma cruzi P2beta (TcP2beta) full-length recombinant protein. The gene encoding the TcP2beta ribosomal protein was cloned in pMAL-c2 and pET-32a vectors that allow the expression of high levels of soluble fusion proteins. A panel of 32 positive and 32 negative sera was assayed with the purified proteins expressed using pMal-c2 (TcP2beta-MBP) and pET-32a (TcP2beta-TRX) vectors and with MBP and TRX purified from pMAL-c2 and pET-32a vectors, respectively. The antigenic behavior of each TcP2beta recombinant protein differed in the diagnostic performance in terms of DI(+) (93.7 for TcP2beta-MBP vs 100% for TcP2beta-TRX), in DI(-) (90.5 for TcP2beta-MBP vs 100% for TcP2beta-TRX) and in cross-reaction with negative sera. To determine if the higher reactivity of expressed pMAL-c2 protein was due to folding during protein expression or to a steric effect related to the protein adsorption at the titration plate, the reactivity of sera against soluble proteins was assessed by ELISA inhibition assays. As each soluble protein preserved its level of reactivity, we concluded that differences in reactivity were due to intrinsic characteristics of the proteins and not to differences in patterns of adsorption to the plates.